ID   TKFC_HUMAN              Reviewed;         575 AA.
AC   Q3LXA3; Q2L9C1; Q53EQ9; Q9BVA7; Q9H895;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   15-MAR-2017, entry version 115.
DE   RecName: Full=Triokinase/FMN cyclase {ECO:0000312|HGNC:HGNC:24552};
DE   AltName: Full=Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing);
DE   Includes:
DE     RecName: Full=ATP-dependent dihydroxyacetone kinase;
DE              Short=DHA kinase;
DE              EC=2.7.1.28;
DE              EC=2.7.1.29;
DE     AltName: Full=Glycerone kinase;
DE     AltName: Full=Triokinase;
DE     AltName: Full=Triose kinase;
DE   Includes:
DE     RecName: Full=FAD-AMP lyase (cyclizing);
DE              EC=4.6.1.15;
DE     AltName: Full=FAD-AMP lyase (cyclic FMN forming);
DE     AltName: Full=FMN cyclase;
GN   Name=TKFC {ECO:0000312|HGNC:HGNC:24552};
GN   Synonyms=DAK {ECO:0000312|HGNC:HGNC:24552};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, FAD-AMP LYASE
RP   ACTIVITY, AND VARIANT THR-185.
RC   TISSUE=Brain;
RX   PubMed=16289032; DOI=10.1016/j.bbrc.2005.10.142;
RA   Cabezas A., Costas M.J., Pinto R.M., Couto A., Cameselle J.C.;
RT   "Identification of human and rat FAD-AMP lyase (cyclic FMN forming) as
RT   ATP-dependent dihydroxyacetone kinases.";
RL   Biochem. Biophys. Res. Commun. 338:1682-1689(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT THR-185, AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RA   Cabezas A., Costas M.J., Pinto R.M., Couto A., Cameselle J.C.;
RT   "Human brain Dha kinase/FMN cyclase splice variant mRNA encoding a
RT   shorter protein inactive as Dha kinase and FMN cyclase.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   THR-185.
RC   TISSUE=Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   THR-185.
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, IDENTITY OF TRIOKINASE AND
RP   DIHYDROXYACETONE KINASE, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=4688871;
RA   Beutler E., Guinto E.;
RT   "Dihydroxyacetone metabolism by human erythrocytes: demonstration of
RT   triokinase activity and its characterization.";
RL   Blood 41:559-568(1973).
RN   [8]
RP   INTERACTION WITH IFIH1.
RX   PubMed=17600090; DOI=10.1073/pnas.0700544104;
RA   Diao F., Li S., Tian Y., Zhang M., Xu L.G., Zhang Y., Wang R.P.,
RA   Chen D., Zhai Z., Zhong B., Tien P., Shu H.B.;
RT   "Negative regulation of MDA5- but not RIG-I-mediated innate antiviral
RT   signaling by the dihydroxyacetone kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:11706-11711(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, DOMAIN, AND MUTAGENESIS OF
RP   THR-112; LYS-204; HIS-221; ASP-401; ASP-403; CYS-404; SER-446 AND
RP   ASP-556.
RX   PubMed=24569995; DOI=10.1074/jbc.M113.525626;
RA   Rodrigues J.R., Couto A., Cabezas A., Pinto R.M., Ribeiro J.M.,
RA   Canales J., Costas M.J., Cameselle J.C.;
RT   "Bifunctional homodimeric triokinase/FMN cyclase: contribution of
RT   protein domains to the activities of the human enzyme and molecular
RT   dynamics simulation of domain movements.";
RL   J. Biol. Chem. 289:10620-10636(2014).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350 AND SER-511, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Catalyzes both the phosphorylation of dihydroxyacetone
CC       and of glyceraldehyde, and the splitting of ribonucleoside
CC       diphosphate-X compounds among which FAD is the best substrate.
CC       Represses IFIH1-mediated cellular antiviral response
CC       (PubMed:17600090). {ECO:0000250|UniProtKB:F1RKQ4,
CC       ECO:0000250|UniProtKB:Q4KLZ6, ECO:0000269|PubMed:16289032,
CC       ECO:0000269|PubMed:17600090, ECO:0000269|PubMed:4688871}.
CC   -!- CATALYTIC ACTIVITY: ATP + glycerone = ADP + glycerone phosphate.
CC       {ECO:0000269|PubMed:4688871}.
CC   -!- CATALYTIC ACTIVITY: ATP + D-glyceraldehyde = ADP + D-
CC       glyceraldehyde 3-phosphate. {ECO:0000269|PubMed:4688871}.
CC   -!- CATALYTIC ACTIVITY: FAD = AMP + riboflavin cyclic-4',5'-phosphate.
CC       {ECO:0000269|PubMed:4688871}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Name=Co(2+); Xref=ChEBI:CHEBI:48828; Evidence={ECO:0000250};
CC       Note=Manganese or cobalt are requested for FAD-AMP lyase activity.
CC       {ECO:0000250};
CC   -!- ENZYME REGULATION: Each activity is inhibited by the substrate(s)
CC       of the other.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.5 uM for dihydroxyacetone {ECO:0000269|PubMed:4688871};
CC         KM=11 uM for glyceraldehyde {ECO:0000269|PubMed:4688871};
CC         KM=1.55 uM for dihydroxyacetone {ECO:0000269|PubMed:24569995};
CC         KM=43.2 uM for ATP {ECO:0000269|PubMed:24569995};
CC         KM=18.1 uM for glyceraldehyde {ECO:0000269|PubMed:24569995};
CC         KM=7 uM for FAD {ECO:0000269|PubMed:24569995};
CC         KM=12 uM for ADP-glucose {ECO:0000269|PubMed:24569995};
CC         KM=317 uM for UDP-glucose {ECO:0000269|PubMed:24569995};
CC         KM=263 uM for UDP-galactose {ECO:0000269|PubMed:24569995};
CC       pH dependence:
CC         Optimum pH is 6.6. {ECO:0000269|PubMed:4688871};
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with IFIH1 (via the
CC       CARD domains), the interaction is inhibited by viral infection
CC       (PubMed:17600090). {ECO:0000250|UniProtKB:F1RKQ4,
CC       ECO:0000269|PubMed:17600090}.
CC   -!- INTERACTION:
CC       O00560:SDCBP; NbExp=3; IntAct=EBI-4291069, EBI-727004;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q3LXA3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q3LXA3-2; Sequence=VSP_057181;
CC         Note=Inactive as DHA kinase and FMN cyclase.;
CC   -!- TISSUE SPECIFICITY: Detected in erythrocytes (at protein level).
CC       {ECO:0000269|PubMed:4688871}.
CC   -!- DOMAIN: DhaK and DhaL domains have differential roles,
CC       individually DhaK is inactive and DhaL displays cyclase but not
CC       kinase activity. {ECO:0000269|PubMed:24569995}.
CC   -!- SIMILARITY: Belongs to the dihydroxyacetone kinase (DAK) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ138290; ABA10576.1; -; mRNA.
DR   EMBL; DQ344550; ABC70184.1; -; mRNA.
DR   EMBL; AK023915; BAB14722.1; -; mRNA.
DR   EMBL; AK223580; BAD97300.1; -; mRNA.
DR   EMBL; AP003108; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001341; AAH01341.1; -; mRNA.
DR   CCDS; CCDS8003.1; -. [Q3LXA3-1]
DR   RefSeq; NP_056348.2; NM_015533.3. [Q3LXA3-1]
DR   RefSeq; XP_016873010.1; XM_017017521.1. [Q3LXA3-1]
DR   RefSeq; XP_016873012.1; XM_017017523.1. [Q3LXA3-2]
DR   UniGene; Hs.6278; -.
DR   ProteinModelPortal; Q3LXA3; -.
DR   SMR; Q3LXA3; -.
DR   BioGrid; 117481; 25.
DR   DIP; DIP-60967N; -.
DR   IntAct; Q3LXA3; 2.
DR   MINT; MINT-5001370; -.
DR   STRING; 9606.ENSP00000378360; -.
DR   iPTMnet; Q3LXA3; -.
DR   PhosphoSitePlus; Q3LXA3; -.
DR   BioMuta; DAK; -.
DR   DMDM; 311033370; -.
DR   REPRODUCTION-2DPAGE; IPI00551024; -.
DR   EPD; Q3LXA3; -.
DR   MaxQB; Q3LXA3; -.
DR   PaxDb; Q3LXA3; -.
DR   PeptideAtlas; Q3LXA3; -.
DR   PRIDE; Q3LXA3; -.
DR   DNASU; 26007; -.
DR   Ensembl; ENST00000394900; ENSP00000378360; ENSG00000149476. [Q3LXA3-1]
DR   GeneID; 26007; -.
DR   KEGG; hsa:26007; -.
DR   UCSC; uc001nre.4; human. [Q3LXA3-1]
DR   CTD; 26007; -.
DR   GeneCards; TKFC; -.
DR   HGNC; HGNC:24552; TKFC.
DR   HPA; HPA039486; -.
DR   HPA; HPA048186; -.
DR   MIM; 615844; gene.
DR   neXtProt; NX_Q3LXA3; -.
DR   OpenTargets; ENSG00000149476; -.
DR   PharmGKB; PA142672014; -.
DR   eggNOG; KOG2426; Eukaryota.
DR   eggNOG; COG2376; LUCA.
DR   GeneTree; ENSGT00390000015415; -.
DR   HOGENOM; HOG000234158; -.
DR   HOVERGEN; HBG079502; -.
DR   InParanoid; Q3LXA3; -.
DR   KO; K00863; -.
DR   PhylomeDB; Q3LXA3; -.
DR   TreeFam; TF313821; -.
DR   BRENDA; 2.7.1.29; 2681.
DR   BRENDA; 4.6.1.15; 2681.
DR   Reactome; R-HSA-168928; RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways.
DR   Reactome; R-HSA-70350; Fructose catabolism.
DR   ChiTaRS; DAK; human.
DR   GeneWiki; DAK_(gene); -.
DR   GenomeRNAi; 26007; -.
DR   PMAP-CutDB; Q3LXA3; -.
DR   PRO; PR:Q3LXA3; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000149476; -.
DR   CleanEx; HS_DAK; -.
DR   ExpressionAtlas; Q3LXA3; baseline and differential.
DR   Genevisible; Q3LXA3; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034012; F:FAD-AMP lyase (cyclizing) activity; IDA:UniProtKB.
DR   GO; GO:0004371; F:glycerone kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050354; F:triokinase activity; IDA:UniProtKB.
DR   GO; GO:0046835; P:carbohydrate phosphorylation; IDA:UniProtKB.
DR   GO; GO:0044262; P:cellular carbohydrate metabolic process; IDA:UniProtKB.
DR   GO; GO:0061624; P:fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate; TAS:Reactome.
DR   GO; GO:0006071; P:glycerol metabolic process; IEA:InterPro.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0039534; P:negative regulation of MDA-5 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045088; P:regulation of innate immune response; IDA:UniProtKB.
DR   InterPro; IPR012734; DhaK_ATP.
DR   InterPro; IPR004006; DhaK_dom.
DR   InterPro; IPR004007; DhaL_dom.
DR   Pfam; PF02733; Dak1; 1.
DR   Pfam; PF02734; Dak2; 1.
DR   SMART; SM01120; Dak2; 1.
DR   SUPFAM; SSF101473; SSF101473; 1.
DR   TIGRFAMs; TIGR02361; dak_ATP; 1.
DR   PROSITE; PS51481; DHAK; 1.
DR   PROSITE; PS51480; DHAL; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cobalt; Complete proteome; FAD;
KW   Flavoprotein; Kinase; Lyase; Magnesium; Manganese; Metal-binding;
KW   Multifunctional enzyme; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase.
FT   CHAIN         1    575       Triokinase/FMN cyclase.
FT                                /FTId=PRO_0000121525.
FT   DOMAIN        9    336       DhaK. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00814}.
FT   DOMAIN      372    571       DhaL. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00813}.
FT   NP_BIND     401    404       ATP. {ECO:0000250}.
FT   NP_BIND     446    447       ATP. {ECO:0000250}.
FT   NP_BIND     494    495       ATP. {ECO:0000250}.
FT   NP_BIND     556    558       ATP. {ECO:0000250}.
FT   REGION       56     59       Dihydroxyacetone binding. {ECO:0000250}.
FT   ACT_SITE    221    221       Tele-hemiaminal-histidine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00814}.
FT   BINDING     109    109       Dihydroxyacetone. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00814}.
FT   BINDING     114    114       Dihydroxyacetone. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00814}.
FT   BINDING     486    486       ATP; via carbonyl oxygen. {ECO:0000250}.
FT   MOD_RES     350    350       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     511    511       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     545    545       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q4KLZ6}.
FT   VAR_SEQ     526    575       SAEAAAEATKNMEAGAGRASYISSARLEQPDPGAVAAAAIL
FT                                RAILEVLQS -> EGGGLVICP (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_057181.
FT   VARIANT     185    185       A -> T (in dbSNP:rs2260655).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:16289032,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.4}.
FT                                /FTId=VAR_028108.
FT   VARIANT     334    334       A -> G (in dbSNP:rs35723406).
FT                                /FTId=VAR_054780.
FT   MUTAGEN     112    112       T->A: Highly decreases kinase activity.
FT                                No effect on FMN cyclase activity.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     204    204       K->A: Slightly decreases kinase activity.
FT                                No effect on FMN cyclase activity.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     221    221       H->A: Abolishes kinase activity but not
FT                                FMN cyclase activity.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     401    401       D->A: Abolishes both kinase and FMN
FT                                cyclase activities.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     403    403       D->A: Abolishes both kinase and FMN
FT                                cyclase activities.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     404    404       C->A: Decreases both kinase and FMN
FT                                cyclase activities.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     446    446       S->A: Decreases both kinase and FMN
FT                                cyclase activities.
FT                                {ECO:0000269|PubMed:24569995}.
FT   MUTAGEN     556    556       D->A: Abolishes both kinase and FMN
FT                                cyclase activities.
FT                                {ECO:0000269|PubMed:24569995}.
FT   CONFLICT      7      7       V -> A (in Ref. 3; BAB14722).
FT                                {ECO:0000305}.
FT   CONFLICT     19     19       A -> S (in Ref. 4; BAD97300).
FT                                {ECO:0000305}.
FT   CONFLICT     75     75       V -> A (in Ref. 3; BAB14722).
FT                                {ECO:0000305}.
FT   CONFLICT    376    376       L -> P (in Ref. 3; BAB14722).
FT                                {ECO:0000305}.
FT   CONFLICT    497    497       D -> G (in Ref. 3; BAB14722).
FT                                {ECO:0000305}.
SQ   SEQUENCE   575 AA;  58947 MW;  4DB8C5326F65122C CRC64;
     MTSKKLVNSV AGCADDALAG LVACNPNLQL LQGHRVALRS DLDSLKGRVA LLSGGGSGHE
     PAHAGFIGKG MLTGVIAGAV FTSPAVGSIL AAIRAVAQAG TVGTLLIVKN YTGDRLNFGL
     AREQARAEGI PVEMVVIGDD SAFTVLKKAG RRGLCGTVLI HKVAGALAEA GVGLEEIAKQ
     VNVVAKAMGT LGVSLSSCSV PGSKPTFELS ADEVELGLGI HGEAGVRRIK MATADEIVKL
     MLDHMTNTTN ASHVPVQPGS SVVMMVNNLG GLSFLELGII ADATVRSLEG RGVKIARALV
     GTFMSALEMP GISLTLLLVD EPLLKLIDAE TTAAAWPNVA AVSITGRKRS RVAPAEPQEA
     PDSTAAGGSA SKRMALVLER VCSTLLGLEE HLNALDRAAG DGDCGTTHSR AARAIQEWLK
     EGPPPASPAQ LLSKLSVLLL EKMGGSSGAL YGLFLTAAAQ PLKAKTSLPA WSAAMDAGLE
     AMQKYGKAAP GDRTMLDSLW AAGQELQAWK SPGADLLQVL TKAVKSAEAA AEATKNMEAG
     AGRASYISSA RLEQPDPGAV AAAAILRAIL EVLQS
//
